News

Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
This was the stock's second consecutive day of losses.
River Journal Online18h
Regeneron Outbid in Effort to Acquire 23andMe
Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...
Why Regeneron Is Falling And Why You Should Avoid It
Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.
Pharmaceutical Technology2d
EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM
Lynozyfic’s global sales are projected to reach $707 million by 2031.
BioPharma Dive23h
FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction
The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
The stock's fall snapped a two-day winning streak.
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...
DOJ Aims to Boot WilmerHale as 23andMe Privacy Reviewer Counsel
WilmerHale shouldn’t be permitted to represent a law professor making privacy-related recommendations about the sale of 23andMe’s customers’ genetic data while also performing work for bidder ...